Biotechnology German biotech firm Evotec today announced a strategic alliance with Danish diabetes care giant Novo Nordisk to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity as well as co-morbidities such as non-alcoholic steatohepatitis (NASH), cardiovascular diseases, and diabetic kidney disease. 22 August 2018